<DOC>
	<DOCNO>NCT00283244</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop dividing . Erlotinib may stop growth tumor cell block enzymes need cell growth . It yet know whether gemcitabine erlotinib effective give alone together treat non-small cell lung cancer . PURPOSE : This randomized phase II trial study gemcitabine erlotinib compare well work give alone together first-line therapy treat old patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Gemcitabine and/or Erlotinib First-Line Therapy Treating Older Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival rate old patient stage IIIB IV non-small cell lung cancer treat gemcitabine hydrochloride v erlotinib hydrochloride v gemcitabine hydrochloride erlotinib hydrochloride first-line therapy . Secondary - Determine response rate patient receive regimen . - Determine overall survival rate patient receive regimen . - Determine toxicity profile regimens patient . - Determine quality life patient receive regimen . OUTLINE : This randomize , open-label , control , parallel group , multicenter study . Patients stratify gender , smoke status ( never light vs current former ) , ECOG performance status ( 0-1 v 2 ) . Patients randomize 1 3 treatment arm . - Arm I : Patients receive gemcitabine hydrochloride IV day 1 8 . Patients progressive disease may cross arm II . - Arm II : Patients receive oral erlotinib hydrochloride daily day 1-21 . - Arm III : Patients receive gemcitabine hydrochloride arm I erlotinib hydrochloride arm II . In arm , treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 2 month 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IIIB IV disease Measurable disease RECIST criterion Treated brain metastasis allow provided patient asymptomatic PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 8.0 g/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 4 time ULN Creatinine ≤ 1.5 time ULN Bilirubin normal No history severe hypersensitivity gemcitabine hydrochloride No severe comorbid illness Able participate quality life assessment PRIOR CONCURRENT THERAPY : Recovered prior oncologic major surgery One prior treatment NSCLC allow provide neoadjuvant adjuvant setting At least 1 year since prior treatment neoadjuvant adjuvant set No concurrent antineoplastic antitumor agent therapy , include chemotherapy , radiotherapy , immunotherapy , hormonal anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>